Raafia Memon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Raafia Memon has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Kashif M. Munir
Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, MD, USA
4 shared publications Ann Miller
1 shared publication- David Levitt
Internal Medicine/Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA
1 shared publication Elizabeth M. Lamos
Division of Endocrinology, Diabetes, & Nutrition Department of Medicine University of Maryland School of Medicine Baltimore Maryland USA
1 shared publication- Elizabeth M. Lamos
Internal Medicine/Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, USA
1 shared publication Elizabeth Streeten
1 shared publication
Latest Publications
- Open Access
- 1 June 2021
- Published by Elsevier in Journal of Clinical and Translational Endocrinology: Case Reports
- Vol. 20
Hyperinsulinemic hypoglycemia, clinical considerations and a case report of a novel GCK mutation
- 1 June 2021
- Published by Elsevier in Journal of Clinical and Translational Endocrinology: Case Reports
- Vol. 20
Open AccessHyperinsulinemic hypoglycemia, clinical considerations and a case report of a novel GCK mutation
- Open Access
- 19 March 2021
- Published by Springer Nature in Cureus
- Vol. 13 (3)
Knowledge of Hemoglobin A1c and Glycemic Control in an Urban Population
Aim: Our study aims to assess the knowledge of hemoglobin A1c (HbA1c) and glycemic control in patients with diabetes mellitus (DM) at an urban academic institution. Methods: This was a retrospective cross-sectional study that included a survey of 100 adult patients with DM. Our patient cohort was divided into those with recent HbA1c < 8.0% and those with HbA1c ≥ 8.0% for subgroup analysis. Results: The majority (71%) of patients correctly defined HbA1c and half were aware of their HbA1c target, but they were unable to correlate the correct average blood glucose for an HbA1c level of 7%. Worse control, defined as an HbA1c level of ≥ 8%, was associated with co-morbid disease, but was not associated with understanding HbA1c definition, target or socioeconomic disparities. Perceived glycemic control was congruent with the actual control in 46% of our patients. Ninety percent of those with HbA1c ≥ 8% perceived their control to be better than it actually was, and 97% of those with HbA1c < 8% perceived their control worse than it actually was (P < 0.00001). Conclusion: Although most patients knew the definition of HbA1c, they were unable to correlate HbA1c with average blood sugar. There remain opportunities to increase education for this vulnerable population with co-morbid disease on the use of the HbA1c disease marker as an education tool.
- 19 March 2021
- Published by Springer Nature in Cureus
- Vol. 13 (3)
Open AccessKnowledge of Hemoglobin A1c and Glycemic Control in an Urban Population
Aim: Our study aims to assess the knowledge of hemoglobin A1c (HbA1c) and glycemic control in patients with diabetes mellitus (DM) at an urban academic institution. Methods: This was a retrospective cross-sectional study that included a survey of 100 adult patients with DM. Our patient cohort was divided into those with recent HbA1c < 8.0% and those with HbA1c ≥ 8.0% for subgroup analysis. Results: The majority (71%) of patients correctly defined HbA1c and half were aware of their HbA1c target, but they were unable to correlate the correct average blood glucose for an HbA1c level of 7%. Worse control, defined as an HbA1c level of ≥ 8%, was associated with co-morbid disease, but was not associated with understanding HbA1c definition, target or socioeconomic disparities. Perceived glycemic control was congruent with the actual control in 46% of our patients. Ninety percent of those with HbA1c ≥ 8% perceived their control to be better than it actually was, and 97% of those with HbA1c < 8% perceived their control worse than it actually was (P < 0.00001). Conclusion: Although most patients knew the definition of HbA1c, they were unable to correlate HbA1c with average blood sugar. There remain opportunities to increase education for this vulnerable population with co-morbid disease on the use of the HbA1c disease marker as an education tool.
- 31 July 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 94 (2) , 322-329
Biochemical follow‐up of nonfunctioning benign thyroid nodules
Objective: For the biochemical follow‐up of benign thyroid nodules, some authors recommend periodic lifelong measurement of thyroid‐stimulating hormone (TSH) to assess for the development of toxic nodules over time. The purpose of this retrospective study was to assess the incidence of thyroid dysfunction over time in patients with benign thyroid nodule(s), with a normal TSH at diagnosis and to identify any factors that may predict biochemical dysfunction over time.Methods: Medical records of patients with the diagnosis of thyroid nodule(s) between January 2011 and August 2014 were reviewed. Patients who had TSH measurement within 1 year of initial diagnostic ultrasound (US) were included.Results: One‐hundred fifty‐seven patients identified with thyroid nodule(s) satisfied inclusion criteria. At a median follow‐up of 45 (34‐63) months, 13 (8.3%) patients developed thyroid dysfunction. The mean initial TSH in the group which developed subclinical hyperthyroidism (0.65 mIU/mL) was statistically different from the group that did not develop thyroid dysfunction (1.37 mIU/mL, P: 0.007). More patients with TSH (P: .022). There was no significant difference in the incidence of thyroid dysfunction on the basis of gender, race, smoking status, TPO Ab positivity and number of nodules at diagnosis.Conclusions: We recommend re‐examining the current practice and clinical utility of frequent TSH monitoring in all patients with thyroid nodules, particularly if initial TSH level is ≥1 mIU/L.
- 31 July 2020
- Published by Wiley in Clinical Endocrinology
- Vol. 94 (2) , 322-329
Biochemical follow‐up of nonfunctioning benign thyroid nodules
Objective: For the biochemical follow‐up of benign thyroid nodules, some authors recommend periodic lifelong measurement of thyroid‐stimulating hormone (TSH) to assess for the development of toxic nodules over time. The purpose of this retrospective study was to assess the incidence of thyroid dysfunction over time in patients with benign thyroid nodule(s), with a normal TSH at diagnosis and to identify any factors that may predict biochemical dysfunction over time.Methods: Medical records of patients with the diagnosis of thyroid nodule(s) between January 2011 and August 2014 were reviewed. Patients who had TSH measurement within 1 year of initial diagnostic ultrasound (US) were included.Results: One‐hundred fifty‐seven patients identified with thyroid nodule(s) satisfied inclusion criteria. At a median follow‐up of 45 (34‐63) months, 13 (8.3%) patients developed thyroid dysfunction. The mean initial TSH in the group which developed subclinical hyperthyroidism (0.65 mIU/mL) was statistically different from the group that did not develop thyroid dysfunction (1.37 mIU/mL, P: 0.007). More patients with TSH (P: .022). There was no significant difference in the incidence of thyroid dysfunction on the basis of gender, race, smoking status, TPO Ab positivity and number of nodules at diagnosis.Conclusions: We recommend re‐examining the current practice and clinical utility of frequent TSH monitoring in all patients with thyroid nodules, particularly if initial TSH level is ≥1 mIU/L.
- Open Access
- 30 March 2020
- Published by Elsevier in Endocrine and Metabolic Science
- Vol. 1 (1-2) , 100048
The Gluten- Grave's Connection: Is There One?
- 30 March 2020
- Published by Elsevier in Endocrine and Metabolic Science
- Vol. 1 (1-2) , 100048
Open AccessThe Gluten- Grave's Connection: Is There One?
- 1 January 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (1) , e17-e18
Doubling of Hemoglobin A1c on PCSK9 Inhibitor Therapy
- 1 January 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (1) , e17-e18
Doubling of Hemoglobin A1c on PCSK9 Inhibitor Therapy
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
A rare case of type-2 familial partial lipodystrophy (FLD type 2) non-Dunnigan type with laminin A/C gene (LMNA) mutation causing multi-organ failure and diabetes mellitus
Introduction: Mutations of the LMNA gene cause a wide range of diseases including lipodystrophy, myopathy [including dilated cardiomyopathy (DCM)], neuropathy and progeroid syndrome, and are collectively known as A-type laminopathies. Case report: A 51-year-old Caucasian male with history of heart, liver and kidney transplants was referred for evaluation and treatment of post-transplant diabetes. He was diagnosed with hypertriglyceridemia at age 38. At 43, he was diagnosed with idiopathic cardiomyopathy. Subsequently, he developed liver failure that was presumed to be secondary to passive congestion from heart failure. He underwent simultaneous heart and liver transplants at 44. By age 51, he developed end stage renal disease, treated with hemodialysis prior to recent renal transplant. He developed post-transplant diabetes and endocrine consult was requested. He was noted to be extremely thin with BMI 17.4 kg/m2 (weight=130 lbs, height=6′1″), with generalized lipodystrophy including face, trunk and extremities. Diabetes was managed with a basal/bolus insulin regimen requiring approximately 1.8 units of insulin/kg to control hyperglycemia suggesting severe insulin resistance. Laboratory evaluation was notable for leptin of 2.5 ng/ml (0.3–13.4). Genetic testing revealed a heterozygous LMNA gene missense mutation (c.1045 C>T; p. Arg349Trp). Since identification of the mutation, metformin was added to the insulin with the goal of improving insulin resistance. Discussion: To date, 19 additional patients have been reported with the c.1045C>T LMNA mutation identified in our patient, including a family with 16 affected members, of whom 4 had renal disease. Patients with c.1045C>T mutations have partial lipodystrophy of the non-Dunnigan type (affecting face and extremities), with the exception of one with Dunnigan-type. In the 19 patients, DCM was noted in less than half and elevated creatine kinase, with or without clinical signs of myopathy, was also noted. Less than half had overt diabetes and at least one had euglycemic insulin resistance. The c.1045 C>T variant was not observed in the NHLBI Exome sequencing project, 1000 Genomes Project or Exome Aggregation Consortium database; however the p.Arg349Trp substitution has been identified in patients with skeletal, cardiac and metabolic phenotypes. Collective evidence supports c.1045 C>T as a likely pathogenic variant for an A-type laminopathy and the multiorgan failure seen in our patient. Multiorgan failure should alert endocrinologists of the possibility of LMNA mutation.
- 8 May 2018
- Published by Bioscientifica in Endocrine Abstracts
A rare case of type-2 familial partial lipodystrophy (FLD type 2) non-Dunnigan type with laminin A/C gene (LMNA) mutation causing multi-organ failure and diabetes mellitus
Introduction: Mutations of the LMNA gene cause a wide range of diseases including lipodystrophy, myopathy [including dilated cardiomyopathy (DCM)], neuropathy and progeroid syndrome, and are collectively known as A-type laminopathies. Case report: A 51-year-old Caucasian male with history of heart, liver and kidney transplants was referred for evaluation and treatment of post-transplant diabetes. He was diagnosed with hypertriglyceridemia at age 38. At 43, he was diagnosed with idiopathic cardiomyopathy. Subsequently, he developed liver failure that was presumed to be secondary to passive congestion from heart failure. He underwent simultaneous heart and liver transplants at 44. By age 51, he developed end stage renal disease, treated with hemodialysis prior to recent renal transplant. He developed post-transplant diabetes and endocrine consult was requested. He was noted to be extremely thin with BMI 17.4 kg/m2 (weight=130 lbs, height=6′1″), with generalized lipodystrophy including face, trunk and extremities. Diabetes was managed with a basal/bolus insulin regimen requiring approximately 1.8 units of insulin/kg to control hyperglycemia suggesting severe insulin resistance. Laboratory evaluation was notable for leptin of 2.5 ng/ml (0.3–13.4). Genetic testing revealed a heterozygous LMNA gene missense mutation (c.1045 C>T; p. Arg349Trp). Since identification of the mutation, metformin was added to the insulin with the goal of improving insulin resistance. Discussion: To date, 19 additional patients have been reported with the c.1045C>T LMNA mutation identified in our patient, including a family with 16 affected members, of whom 4 had renal disease. Patients with c.1045C>T mutations have partial lipodystrophy of the non-Dunnigan type (affecting face and extremities), with the exception of one with Dunnigan-type. In the 19 patients, DCM was noted in less than half and elevated creatine kinase, with or without clinical signs of myopathy, was also noted. Less than half had overt diabetes and at least one had euglycemic insulin resistance. The c.1045 C>T variant was not observed in the NHLBI Exome sequencing project, 1000 Genomes Project or Exome Aggregation Consortium database; however the p.Arg349Trp substitution has been identified in patients with skeletal, cardiac and metabolic phenotypes. Collective evidence supports c.1045 C>T as a likely pathogenic variant for an A-type laminopathy and the multiorgan failure seen in our patient. Multiorgan failure should alert endocrinologists of the possibility of LMNA mutation.